Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia

Overview of attention for article published in OncoTargets and therapy, February 2017

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter: 1 X user
patent: 9 patents

reddit: 1 Redditor

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 31 Mendeley

Summary X Patents Reddit Dimensions citations

So far, Altmetric has seen 9 patents that reference this research output.

Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1…

Grant US-11497756-B2

United States of America

Alvocidib prodrugs and their use as protein kinase inhibitors

Grant US-11279694-B2

United States of America

CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer

Grant US-11034710-B2

United States of America

Combination therapies for treatment of cancer

Grant US-10835537-B2

United States of America

Combination therapies for treatment of cancer

Grant US-10682356-B2

United States of America

Predicting response to alvocidib by mitochondrial profiling

Grant US-10624880-B2

United States of America

Combination therapies for treatment of cancer

Grant US-10568887-B2

United States of America

Alvocidib prodrugs having increased bioavailability

Grant US-10562925-B2

United States of America

Profiling peptides and methods for sensitivity profiling

Grant US-10422788-B2

United States of America